A New Jersey leader in economic development is impressed by New Jersey Institute of Technology’s efforts to commercialize research, forge international partnerships and generally be “commercially minded.” Joseph Kelley, deputy chief of staff for economic growth under N.J. Gov. Phil Murphy, reflected on some of NJIT’s past successes after a meeting on campus with deans, department heads, research leaders, the interim provost and top administrators, including Chief External Affairs Officer Angela Garretson and President Teik C. Lim.

Kelley described the launch and sale of cell and gene therapy company BioCentriq by NJIT’s New Jersey Innovation Institute as “hugely important.” A South Korean company, GC Corp., bought the company in 2022 — three years after NJII launched it — and its operation remains based in N.J. To read the full story.